UM171-expanded cord blood transplants support robust T cell reconstitution with low rates of severe infections

Use of cord blood (CB) as a stem cell source extends the curative potential of hematopoietic stem cell (HSC) transplantation (HSCT) for patients with hematologic malignancies for whom HLA-matched sibling and unrelated donors (MUD) are unavailable [1]. Although the overall survival results for CB transplantation are generally comparable to the results obtained with HLA-matched transplants owing to lower incidence of chronic GVHD and relapse, CB transplants have a higher rate of delayed engraftment and transplant-related mortality (TRM).

Source: Biology of Blood and Marrow Transplantation - October 2, 2020 Category: Hematology Authors: Maude Dumont-Lagac é, Qi Li, Mégane Tanguay, Jalila Chagraoui, Tibila Kientega, Guillaume B. Cardin, Ann Brasey, Assya Trofimov, Cédric Carli, Imran Ahmad, Nadia M. Bambace, Léa Bernard, Thomas L. Kiss, Jean Roy, Denis-Claude Roy, Sébastien Lemieux, Source Type: research